ARS Pharmaceuticals, Inc. (SPRY) Misses Q3 EPS by 6c

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q3 EPS of ($0.52), $0.06 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $32.5 million versus the consensus estimate of $28.56 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Citi reiterates Buy rating on AMD with $575 price target post TMT conference
• The Trade Desk (TTD) PT Raised to $14 at Evercore ISI